Reprogramming of liver to pancreas
Related documents:This repository does not currently have the full-text of this item.
You may be able to access a copy if URLs are provided below. (Contact Author)
Islet grafts have demonstrated that patients with diabetes would benefit greatly by beta-cell therapy. However, the paucity of available islets for transplantation as well as the immunological barriers faced in allogeneic transplantation represent a tremendous barrier to regenerative approaches to the treatment of diabetes. Here, we present a strategy and protocols to transdifferentiate developmentally related hepatocytes into beta-cells by the ectopic expression of critical beta-cell transcription factors.
|Item Type||Conference or Workshop Items (UNSPECIFIED)|
|Creators||Thowfeequ, S., Li, W.-C., Slack, J. M. and Tosh, D.|
|Editors||Audet, J.and Stanford, W. L.|
|Departments||Faculty of Science > Biology & Biochemistry|
Actions (login required)